Novo’s Wegovy pill tracks over 26,000 prescriptions
Jan 30 (Reuters) – Novo Nordisk’s Wegovy pill hits over 26,000 U.S. prescriptions in the second full week…
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s new once-daily pill for weight management, designed…
Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss
This article first appeared on GuruFocus. Roche Holding AG (RHHBY) is beginning to show tangible progress in obesity…
How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
This Healthcare Stock Could Soar by 40% in 2026
Novo Nordisk had a rough stretch in 2025 that eventually led to it “firing” its CEO. The new…
JPM 2026: Novo Nordisk’s Jacob Peterson on the Future of Obesity Therapeutics
Novo Nordisk is doubling down on obesity and diabetes. Speaking with Inside Precision Medicine at the 2026 J.P.…
Ozempic Brings Back the ‘Mac vs PC’ Ads for the GLP-1 Era
Novo Nordisk’s Ozempic kicked off the GLP-1 craze when it launched in 2018 for the treatment of Type…
GLP-1 drugs transforming obesity and diabetes care in San Antonio
GLP-1 medications have transformed obesity and weight management care in the U.S. and in San Antonio. And with…
Which Is the Better Stock Buy?
Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified…
How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…